Media Articles Related to Lanoxicaps (Digoxin)
More Digoxin Cautions in AF, HF: Analysis Sees Mortality Risk
Source: theheart.org | Medscape Cardiology Headlines [2015.05.13]
For now, clinicians had "better think twice before prescribing digoxin," an author says, noting that he prescribes the drug "only very occasionally" if he feels there's no other option.
Heartwire from Medscape
Heart Drug Digoxin May Not Be Best for Some Heart Patients
Source: MedicineNet Atrial Fibrillation Specialty [2015.05.06]
Title: Heart Drug Digoxin May Not Be Best for Some Heart Patients
Category: Health News
Created: 5/5/2015 12:00:00 AM
Last Editorial Review: 5/6/2015 12:00:00 AM
Digoxin increases the risk of death in patients with heart problems, according to the largest study of the evidence so far
Source: Cardiovascular / Cardiology News From Medical News Today [2015.05.05]
There is conflicting evidence about whether digoxin, a drug that has been used worldwide for centuries to treat heart disease, might contribute to an increase in deaths in patients with atrial...
New analytics model predicts readmission of congestive heart failure patients
Source: IT / Internet / E-mail News From Medical News Today [2015.05.15]
Readmission of patients with chronic diseases is a growing problem, costing the U.S. health care system about $25 billion each year.
Congestive Heart Failure (CHF)
Source: MedicineNet Group B Strep Specialty [2014.12.29]
Title: Congestive Heart Failure (CHF)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 12/29/2014 12:00:00 AM
Published Studies Related to Lanoxicaps (Digoxin)
Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the
pharmacokinetics of digoxin. 
To investigate the impact of the direct Factor Xa inhibitor darexaban
administered in a modified-release formulation (darexaban-MR) on the
pharmacokinetic (PK) profile of digoxin. In this Phase I, randomized,
double-blind, two-period crossover study (8 days for each treatment, 10 days
washout), 24 healthy subjects received darexaban-MR 120 mg once/day (qd) +
digoxin 0.25 mg qd in one treatment period, and placebo + digoxin 0.25 mg qd in
the other treatment period...
The study of antiarrhythmic medications in infancy (SAMIS): a multicenter,
randomized controlled trial comparing the efficacy and safety of digoxin versus
propranolol for prophylaxis of supraventricular tachycardia in infants. 
CONCLUSIONS: There was no difference in SVT recurrence in infants treated with
Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. [2011.03]
The aim of this study was to investigate whether multiple doses of the oral and highly selective dipeptidyl peptidase-4 inhibitor linagliptin affect the steady-state pharmacokinetics of the P-glycoprotein substrate digoxin. This single-center, open-label, two-period cross-over study involved healthy subjects (n = 20), randomized to treatment sequence AB or BA, where A comprised 0.25 mg digoxin qd for 5 days, then 0.25 mg digoxin qd plus 5 mg linagliptin qd for 6 days, and B comprised 0.25 mg digoxin qd for 11 days...
Digoxin for preventing or treating neonatal respiratory distress syndrome. [2011.01.19]
CONCLUSIONS: Although hemodynamic disturbances play a role in the overall pathogenesis of respiratory distress syndrome, the specific contribution of early congestive heart failure (unrelated to hemodynamically significant patent ductus arteriosus) does not appear to be a significant factor in RDS. Treatment with digoxin has no proven value in infants solely affected with RDS.
Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). [2010.09]
Several retrospective studies have raised concerns regarding digoxin therapy in select subgroups of heart failure patients... No benefit with digoxin use was observed in this study, underscoring the need to reassess the role of digoxin in the contemporary management of heart failure.
Clinical Trials Related to Lanoxicaps (Digoxin)
A Phase 1 Study Evaluating Eliglustat's Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy Adults [Recruiting]
The primary objective of this study is to determine the effect of repeat oral doses of
eliglustat 150 mg twice daily (BID) (or 100 mg BID for CYP2D6 poor metabolizers) on the
pharmacokinetics (PK) of orally administered digoxin 0. 25 mg in healthy adult subjects. This
will be a single-site, open-label study in 2 staggered cohorts of healthy adult subjects.
The study will comprise a screening period (between Day - 45 and Day -2), treatment period 1
(Day - 1 to Day 4), treatment period 2 (Day 11 to Day 18), and a safety follow-up visit (Day
24 ± 1). There will be a 10-day washout between dosing of study drug in Period 1 and Period
2. The duration of each subject's participation in the study, inclusive of the screening and
follow-up visits, will be approximately 10 weeks.
Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients [Recruiting]
The purpose of this study is to determine whether AZD1656 will affect the pharmacokinetics
(PK) of digoxin in type 2 diabetes mellitus (T2DM) patients.
A Trial of Digoxin Before Second-Trimester Abortion [Recruiting]
Clinical Trial to Evaluate the Influence of Genotype and DDIs of Aspirin on the PK/PD of Clopidogrel and PK of Digoxin [Recruiting]
A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Subjects [Recruiting]
The purpose of this study is to study how the body processes digoxin and the effect of
dulaglutide on how digoxin is processed by the body. Information about any side effects that
may occur will also be collected.
This study is for research purposes only and is not intended to treat any medical condition.
This research study requires that a blood sample be obtained and stored for future research
involving genetic analysis.